Johnson and Johnson Archives -

Heather Barnes, external innovation lead EMEA at Johnson and Johnson Consumer Health, is a scientist who is truly

Consumer health innovation – where passion and science meet

https://pharmaphorum.com/sales-marketing/consumer-health-innovation-jnj/

Oncology/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

The top 5 pharma M&A deals of 2020

George Underwood Gilead, J&J, Johnson and Johnson, M&A, Merck & Co, MSD, Sanofi 0 Comment

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout

The top 5 pharma M&A deals of 2020

https://pharmaphorum.com/views-and-analysis/the-top-5-pharma-ma-deals-of-2020/

Charities bankroll coronavirus drug hunt as outbreak hits economies

News

Nothing should stand in the way of coronavirus vaccine access, says J&J

George Underwood coronavavirus vaccine, coronavirus, COVID-19, Janssen, Johnson and Johnson 0 Comment

Janssen’s chief scientific officer and worldwide chairman Paul Stoffels has said he hopes the company’s coronavirus vaccine candidate

Nothing should stand in the way of coronavirus vaccine access, says J&J

https://pharmaphorum.com/news/nothing-should-stand-in-the-way-of-coronavirus-vaccine-access-says-jj/

R&D/ Views & Analysis/ Views and analysis

Johnson & Johnson: Partnering to eliminate disease

George Underwood J&J, Johnson and Johnson, Oliver Stohlmann, world without disease 0 Comment

J&J’s global head of external innovation communication on how partnerships are fuelling the company’s vision for a World

Johnson & Johnson: Partnering to eliminate disease

https://pharmaphorum.com/views-and-analysis/johnson-johnson-partnering-to-eliminate-disease/

News/ News/ R&D

Zytiga generics looming as US court nixes J&J patent

Phil Taylor cancer, Johnson and Johnson, Zytiga 0 Comment

Johnson & Johnson has lost another round in its patent defence for prostate cancer blockbuster Zytiga, raising the

Zytiga generics looming as US court nixes J&J patent

https://pharmaphorum.com/news/zytiga-generics-looming-as-us-court-nixes-jj-patent/

News/ News/ R&D

J&J builds case for HIV vaccine ahead of pivotal trial readout

Phil Taylor HIV, HIV vaccine, Johnson and Johnson 0 Comment

Johnson & Johnson has moved a step closer to the goal of developing a vaccine that can help

J&J builds case for HIV vaccine ahead of pivotal trial readout

https://pharmaphorum.com/news/jj-builds-case-hiv-vaccine/

Insights/ Sales and Marketing/ Views & Analysis/ Views and analysis

J&J tops the pharma market cap charts – but for how long?

Piotr Wnuk AbbVie, Amazon, Google, Johnson and Johnson, Merck KGaA, Roche, Takeda, top pharma companies, top pharmaceutical companies 0 Comment

Data and analytics firm GlobalData has tracked the market cap and performance of the top 25 pharma companies

J&J tops the pharma market cap charts – but for how long?

https://pharmaphorum.com/views-and-analysis/jj-tops-pharma-market-cap-charts-long/

Diabetes/ Diabetes/ Healthcare/ News/ News/ Patients

J&J seals $2.1bn deal on sale of major diabetes devices firm

Joy Persaud blood glucose monitor, Diabetes, Glucose, J&J, Johnson and Johnson, Platinum Equity 0 Comment

As part of its ongoing divestment program, a deal worth $2.1 billion has been struck between Johnson &

J&J seals $2.1bn deal on sale of major diabetes devices firm

https://pharmaphorum.com/news/jj-deal-glucose-monitoring-system/

News/ News/ Top pharmaceutical companies

J&J offered $2.7 billion for sterilisation business by Fortive

Linda Banks ASP, Fortive, infection, J&J, Johnson and Johnson, medical devices, pharma deal, sterilisation 0 Comment

Johnson & Johnson (J&J) has announced that Fortive Corp has made an offer of about $2.7 billion in cash for its Advanced Sterilisation Products (ASP) business.

J&J offered $2.7 billion for sterilisation business by Fortive

https://pharmaphorum.com/news/jnj-sterilisation-business-fortive/

Trending

Johnson and Johnson

Login